These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 11158089)

  • 1. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates.
    Tsongalis GJ; Gleeson T; Rodina M; Anamani D; Ross J; Joanisse I; Tanimoto L; Ziermann R
    J Clin Virol; 2005 Dec; 34(4):268-71. PubMed ID: 16286050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
    Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal use of a line probe assay for human immunodeficiency virus type 1 protease predicts phenotypic resistance and clinical progression in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Plesséria JM; Fontaine E; Robert I; Arendt V; Staub T; Hemmer R; Schneider F; Schmit JC
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1928-33. PubMed ID: 12019110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
    Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
    Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
    Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
    Roque-Afonso AM; Férey MP; Mackiewicz V; Fki L; Dussaix E
    Antivir Ther; 2003 Dec; 8(6):627-34. PubMed ID: 14760897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
    Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
    Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
    O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
    J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of genotypic resistance among antiretroviral drug-naive HIV-1-infected patients in Belgium.
    Van Vaerenbergh K; Debaisieux L; De Cabooter N; Declercq C; Desmet K; Fransen K; Maes B; Marissens D; Miller K; Muyldermans G; Sprecher S; Stuyver L; Vaira D; Verhofstede C; Zissis G; Van Ranst M; De Clercq E; Desmyter J; Vandamme AM
    Antivir Ther; 2001 Mar; 6(1):63-70. PubMed ID: 11417763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.
    Svedhem V; Lindkvist A; Lidman K; Sönnerborg A
    J Med Virol; 2002 Dec; 68(4):473-8. PubMed ID: 12376953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
    Wilson JW; Bean P; Robins T; Graziano F; Persing DH
    J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluating the therapeutic care of HIV infection in Tunisia].
    Jlizi A; Slim A; Benammar Elgaaied A; Ben Rejab S; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M
    Tunis Med; 2008 Jun; 86(6):534-9. PubMed ID: 19216443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.